Stereotaxis Inc. Announces Third‑Quarter 2026 Financial Results Release
Stereotaxis Inc. (NYSE MKT: STXS), a prominent provider of robotic systems and instruments for minimally invasive endovascular procedures, has scheduled the publication of its third‑quarter 2026 financial results for November 10, 2026. The company will announce the figures following the close of U.S. markets and will subsequently host a conference call and webcast to discuss the results and other corporate developments.
The announcement, issued by senior executives, underscores Stereotaxis’s leadership in the surgical‑robotics arena. The firm notes its mission to advance robotic systems, instruments and information solutions for interventional laboratories, and highlights its global reach: more than 150,000 patients worldwide have benefited from procedures that employ Stereotaxis technology.
Investors and market observers have noted that the stock has experienced a decline of –26.47 % since the end of last month, trading at USD 1.00 per share after a –0.99 % movement during the 24‑hour period ending at 08:09 PM Central Europe on Wednesday, 21 st. With a current supply of 100.2 million shares, the market capitalisation stands at USD 101.2 million. The 200‑day simple moving average is USD 1.77, and the 52‑week high and low were USD 3.15 (10/24/2025) and USD 0.95 (10/19/2026) respectively. In the most recent 24‑hour window, approximately USD 636.7 k of Stereotaxis shares were traded.
Related Market Activity
In the past 24 hours, several peer companies have shown varied performance:
| Ticker | 24‑hour Change | Current Price | Market Cap | Notable Commentary |
|---|---|---|---|---|
| AREC | –2.65 % | USD 1.10 | USD 120.9 million | Shares traded above fundamental value; modest decline of ~3 %. |
| NSTR | +3.45 % | USD 3.12 | USD 119.4 million | Post‑effective amendment to Form F‑4 following business combination with Viking Acquisition Corp.; transition to Canadian corporation. |
| BYRN | –4.64 % | USD 4.90 | USD 121 million | Downtrend continues. |
| OTLK | +5.48 % | USD 0.55 | USD 120 million | Positive momentum. |
| SKYA | +1.43 % | USD 2.90 | USD 119.9 million | Announces tender offer to repurchase up to 95 % of outstanding shares at USD 3.00 per share; proceeds from liquidation of Solana holdings. |
Company Overview
Founded in 2004, Stereotaxis Inc. designs, manufactures, and markets advanced cardiology instrument control systems for coronary artery disease and arrhythmia treatment. The company’s flagship Stereotaxis System is available in the United States and Europe and is listed on the NYSE MKT exchange. The firm’s website, www.stereotaxis.com , provides comprehensive product information and investor relations resources.
Investor Contact
The company has supplied contact information for investor inquiries in the announcement. Stakeholders are encouraged to attend the scheduled webcast to obtain further insight into the forthcoming financial results and the strategic direction of Stereotaxis Inc.
This article is intended for informational purposes only and does not constitute investment advice.
